Test for
Cancer
Detecting cancer at the earliest stage
significantly increases patient survival rates
Test for Cancer
- Simple Blood Test for Cancer
- Detects Absence of Cancer
- Indicates Risk of Cancer Presence
- Annual Screening To Catch Cancer Early
Why HrC Genomics?
- One test for all cancers
- Detects cancer earlier than other blood tests
- Detects cancer earlier than MRI, CT & PET Scans
- Highly accuate & reliable results
A New Chapter in Cancer Diagnostics
The ground-breaking HrC technology is the result of dedicated research by a team of Indian scientists at Epigeneres Biotech in Mumbai, led by the late Dr. Vinay Kumar Tripathi. Their journey began when they were evaluating a drug designed to interact with a cancer pathway. During this process, they made a serendipitous observation: the drug was specifically affecting a small population of cells.
This led to a deeper investigation, which revealed a crucial epigenetic change happening in stem cells. This change was effectively transforming them into cancer stem cells. These newly formed cancer stem cells would then go on to create more cancer cells, which eventually come together to form a discernible tumour.
Click here to read the full story.
Screening with HrC Genomics
- Simple blood test for cancer.
- Samples processed using Next Generation Sequencing (NGS) technology.
- The test delivers a result for when cancer is NOT present.
- Detects early indicators of cancer presence which can be monitored through annual testing.
- Detects risk of cancer presence earlier than any other known technology i.e., MRI, CT, PET and other liquid biopsy technology.
- Works for all types of cancer – solid tumours, blood cancers and soft tissue sarcomas.
- Can be used to monitor cancer survivors for risk of cancer recurrence.
- Minimally invasive procedure means that the test can be taken as often as required.
- Full report issued displaying the HrC Score and a detailed analysis of any dysregulated cancer pathways.
B-Cube Onco (Blood Based Biopsy)
B-Cube Onco provides a Full Cancer Health Check of all the organs impacted by cancer. This is possible due to the discovery by our scientists of pluripotent progenitor stem cells circulating in peripheral blood. This type of stem cell contains the signature of the organ from where it originated meaning that once the transcriptome analysis of the cell has been performed, detailed information relating to the tumour(s) can be provided i.e., Genetic Mutations, Altered Expressions & Dysregulated Pathways.
B-Cube Onco is a simple blood test that provides all the information required to guide treatment for all organs impacted by cancer, without the need for a tissue biopsy.
Being a simple blood test, B-Cube Onco can be performed as often as required to help monitor responsiveness to treatment , as well as being able to conclusively confirm remission for cancer survivors.
Simple Blood Test, Amazing Results
- A simple, innovative blood test to assess cancer risk.
- Uses RNA from enriched stem cells in peripheral blood for a transcriptomic profile.
- Employs Next Generation Sequencing (NGS) for Whole Transcriptome Sequencing (WTS) for precision.
- Identifies altered differentially expressed genes and dysregulated genetic pathways, based on the standard Pathways in Cancer (PIC) and proprietary gene panels.
- Tissue transcriptome can detect ‘organ-specific’ signature only.
- B-Cube Onco assesses cancer risk by analysing genes from ALL organs.
- Detects systemic underlying / residual malignancy using standard gene-disease associations, which correlates with total tumour burden.
- Captures tumour (intra-tumour, intra-organ and inter-organ) heterogeneity which is missed by standard tumour tissue analysis from resection or biopsy (point malignancy).
Types of B-Cube Onco Reports
- Occurrence Risk Assessment (for asymptomatic screening subjects)
- Response Assessment (for cancer patients on treatment)
- Remission assessment (for cancer patients close to remission)
- Recurrence Risk Assessment (for cancer survivors)
Cancer’s unpredictable nature makes it a formidable foe. Early detection is critical for successful treatment and survival, but often, cancer develops silently.
HrC Genomics offers a proactive solution. This technology analyses specific biomarkers in your blood, providing insights into your cancer risk before symptoms appear.
This is especially crucial for individuals at high risk due to family history, exposure to carcinogens (like asbestos or radon), or lifestyle factors like smoking. Understanding your risk empowers you to take action.
Early detection through blood testing allows for timely intervention, significantly improving outcomes and potentially saving lives. It’s a proactive step towards safeguarding your health.